Roche commits $750 million to double Oregon plant capacity as obesity drug push grows

Roche's Genentech announced a $750 million investment to enlarge its device fill-finish facility in Hillsboro, Oregon.

The expansion will double the plant's size and add end-to-end capabilities for pre-filled syringes and autoinjectors, supporting its upcoming obesity drug pipeline.

The project is expected to create about 250 manufacturing jobs and 200 construction positions, with commercial operations targeted for 2031.

The move follows Roche's earlier $2 billion commitment to a new manufacturing complex in Holly Springs, North Carolina, aimed at scaling production of next-generation metabolic medicines as the company seeks a top-three position in the obesity market.